NEWS
- Pharma & Biotech News #PharmaBuzz
- Weekly News Recap #Phispers
- Recent Product Approvals #GreenLight
- Quality Compliance Alerts #Warning!
- All News #Library
DRUGS & DEVELOPMENTS
MARKET INTEL by PharmaCompass
Create content with us, ask us
By PharmaCompass
2019-02-14
Impressions: 133 Article
In the US, Johnson & Johnson has put up a good example of self-regulation — it said it will put list prices of its drugs in their television commercials. This way, J&J would become the first pharmaceutical company to take that step, ahead of a proposed Trump administration rule that would force all pharma companies to add list prices to TV advertisements.
The pharmaceutical industry has largely opposed this proposed rule, arguing that few people pay the high list prices. Some people’s out-of-pocket costs, though, are based on list prices.
The first drug to see this change is Janssen’s oral anticoagulant Xarelto. By March, Janssen will add both the list price and the potential out-of-pocket costs to its TV commercials. The information will appear on screen at the end of the commercial and will include a website where people can enter insurance information to get more specific costs.
Without insurance, Xarelto costs US$ 450 to US$ 540 per month, depending on the pharmacy. About 1 million Xarelto prescriptions are filled in the US each month.
In a statement, J&J said it will add prices to its other medicines too. It plans to weigh patient and consumer feedback on the Xarelto changes as it rolls out the follow-ups.
Members of the trade association PhRMA have recommended that TV ads start listing a website that gives consumers possible out-of-pocket costs and list prices. Last month, Eli Lilly began listing a website in its ads for diabetes medicine Trulicity.
The PharmaCompass Newsletter – Sign Up, Stay Ahead
Feedback, help us to improve. Click here
Image Credit : #Phisper Infographic by SCORR MARKETING & PharmaCompass is licensed under CC BY 2.0
“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”
